Jul 13th 2012 - Edison Investment Research today published a report on 4SC entitled "IIb Or Not IIb – That Is The Question". In summary, the report says:
4SC faces a strategic challenge following its recent €12.6m fund-raising, namely whether to take vidofludimus into a Phase IIb study in Crohn’s disease ahead of a partnering deal (for either it or resminostat). With pro forma cash of c €24m, it probably has the resources to do so, but financially this would be a risky decision. 4SC maintains its preference would be to conduct this (and a planned Phase III trial for resminostat in advanced liver cancer) with a partner (or partners). However, if it can secure a licensing deal on one of its two lead products, it could allow the advancement of the other independently, potentially allowing capture of the full value from a positive result.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »